Your browser is no longer supported. Please, upgrade your browser.
BYSI [NASD]
BeyondSpring Inc.
Index- P/E- EPS (ttm)-2.04 Insider Own71.61% Shs Outstand33.96M Perf Week-2.52%
Market Cap391.84M Forward P/E- EPS next Y-1.79 Insider Trans0.00% Shs Float11.14M Perf Month1.00%
Income-61.00M PEG- EPS next Q-0.54 Inst Own16.90% Short Float10.77% Perf Quarter-36.21%
Sales0.20M P/S1959.19 EPS this Y-31.60% Inst Trans0.32% Short Ratio5.84 Perf Half Y-36.33%
Book/sh2.60 P/B3.87 EPS next Y20.40% ROA-103.10% Target Price- Perf Year-41.03%
Cash/sh2.81 P/C3.58 EPS next 5Y- ROE-150.40% 52W Range9.24 - 21.50 Perf YTD-17.54%
Dividend- P/FCF- EPS past 5Y-31.10% ROI-71.00% 52W High-54.79% Beta0.54
Dividend %- Quick Ratio8.20 Sales past 5Y- Gross Margin- 52W Low5.19% ATR0.59
Employees91 Current Ratio8.20 Sales Q/Q- Oper. Margin- RSI (14)42.13 Volatility5.68% 5.94%
OptionableYes Debt/Eq0.02 EPS Q/Q0.10% Profit Margin- Rel Volume0.64 Prev Close10.06
ShortableYes LT Debt/Eq0.02 EarningsApr 30 BMO Payout- Avg Volume205.34K Price9.72
Recom1.60 SMA20-3.94% SMA50-11.24% SMA200-22.26% Volume40,549 Change-3.38%
Apr-05-21Downgrade H.C. Wainwright Buy → Neutral
Jan-11-21Initiated BofA Securities Buy $25
Dec-29-20Initiated Evercore ISI Outperform $30
Feb-07-20Initiated Jefferies Buy $25
Jan-10-20Initiated Nomura Buy $34
Dec-03-19Initiated William Blair Outperform
Jul-10-19Reiterated H.C. Wainwright Buy $60 → $41
Apr-30-19Downgrade Maxim Group Buy → Hold
Oct-25-18Reiterated Maxim Group Buy $48 → $35
May-10-21 08:18AM  
Apr-30-21 06:01PM  
08:00AM  
07:00AM  
Apr-28-21 04:37PM  
Apr-27-21 11:22AM  
Apr-01-21 07:11AM  
Mar-31-21 11:21PM  
Mar-21-21 04:14AM  
Mar-11-21 04:01PM  
Jan-11-21 10:06AM  
Dec-29-20 03:27PM  
09:19AM  
08:00AM  
Dec-17-20 08:00AM  
Dec-10-20 08:00AM  
Nov-29-20 09:45AM  
Nov-24-20 08:59PM  
Nov-23-20 04:01PM  
Nov-19-20 08:00AM  
Nov-17-20 04:01PM  
08:00AM  
Nov-16-20 07:00AM  
Nov-13-20 04:46PM  
07:00AM  
Oct-14-20 07:00AM  
Oct-12-20 07:00AM  
Sep-29-20 08:00AM  
Sep-24-20 08:00AM  
Sep-22-20 08:30AM  
07:43AM  
Sep-11-20 08:00AM  
Sep-10-20 08:37AM  
Sep-08-20 07:00AM  
Sep-03-20 03:30PM  
07:00AM  
Aug-27-20 08:00AM  
Aug-18-20 08:00AM  
Aug-11-20 08:00AM  
Jun-30-20 07:00AM  
Jun-24-20 12:02AM  
Jun-23-20 08:00AM  
Jun-19-20 05:32AM  
Jun-18-20 04:06PM  
Jun-15-20 07:00AM  
Jun-11-20 08:00AM  
Jun-09-20 08:00AM  
Jun-03-20 08:00AM  
Jun-02-20 08:00AM  
May-13-20 08:00AM  
May-01-20 08:00AM  
Apr-30-20 05:05PM  
07:00AM  
Apr-29-20 08:00AM  
Apr-23-20 08:00AM  
Mar-30-20 08:00AM  
Mar-26-20 11:06AM  
Mar-23-20 09:00AM  
Mar-11-20 08:00AM  
Feb-10-20 08:00AM  
Jan-23-20 08:00AM  
Jan-06-20 08:00AM  
Dec-19-19 08:00AM  
Dec-18-19 07:00AM  
Dec-11-19 09:01AM  
Dec-10-19 08:02AM  
Dec-09-19 08:01AM  
Nov-11-19 08:00AM  
Nov-06-19 08:05AM  
Oct-25-19 09:01AM  
Oct-24-19 04:03PM  
Oct-23-19 08:00AM  
Oct-17-19 08:00AM  
Oct-08-19 08:00AM  
Oct-01-19 08:00AM  
Sep-26-19 12:39PM  
Sep-23-19 08:00AM  
Sep-18-19 07:00AM  
06:00AM  
Sep-11-19 08:00AM  
Sep-10-19 08:00AM  
Sep-06-19 07:00AM  
Aug-23-19 08:00AM  
Jul-17-19 09:05AM  
Jul-16-19 04:07PM  
Jul-10-19 08:23AM  
Jun-28-19 02:19PM  
Jun-20-19 08:00AM  
Jun-04-19 08:00AM  
May-20-19 08:03AM  
May-16-19 08:01AM  
Apr-30-19 04:15PM  
11:23AM  
07:30AM  
06:00AM  
Apr-24-19 04:30PM  
Apr-04-19 04:30PM  
Mar-26-19 07:30AM  
Mar-25-19 07:30AM  
Mar-20-19 07:30AM  
BeyondSpring Inc., a clinical stage biopharmaceutical company, together with its subsidiaries, focuses on the development and commercialization of immuno-oncology cancer therapies. The company's lead asset is the Plinabulin that is in late stage clinical trials as an anti-cancer agent in combination with docetaxel in advanced non-small cell lung cancer (NSCLC) for the prevention of high and intermediate risk chemotherapy-induced neutropenia. It is also developing Plinabulin in combination with various immuno-oncology agents, including nivolumab, a programmed cell death protein 1 antibody for the treatment of NSCLC; nivolumab and ipilimumab, a CTLA-4 antibody to treat small cell lung cancer; and death protein 1 or programmed death-ligand 1, an antibodies and radiation or chemotherapy for the treatment of multiple cancers. In addition, the company engages in the development of three small molecule immune agents in preclinical stages; and a drug development platform using ubiquitin mediated protein degradation pathway. BeyondSpring Inc. has collaboration agreements with the Fred Hutchinson Cancer Research Center and the University of Washington. The company was founded in 2010 and is headquartered in New York, New York.